非在研机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2016-02-18), |
最高研发阶段(中国)申请上市 |
特殊审评- |
分子式C18H15FeO9 |
InChIKeyAHPWLYJHTFAWKI-UHFFFAOYSA-K |
CAS号33725-54-1 |
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 贫血 | 临床3期 | 英国 | 2022-05-30 | |
| 结肠癌 | 临床3期 | 英国 | 2022-05-30 | |
| 炎症性肠病 | 临床3期 | 中国 | 2021-09-01 | |
| 慢性肾病 | 临床3期 | 美国 | 2016-12-01 | |
| 溃疡性结肠炎 | 临床3期 | - | 2011-08-01 | |
| 克罗恩病 | 临床3期 | - | 2011-08-01 |
临床2期 | 41 | (NYHA class II) | 鹹願鏇艱衊願積餘齋積(夢鬱簾蓋餘選製構網衊) = 觸窪鹽夢餘廠鹹淵鬱繭 壓蓋獵淵膚艱夢選積範 (鹽顧築範獵糧餘齋壓壓 ) 更多 | 积极 | 2026-08-28 | ||
(NYHA class III-IV) | 鹹願鏇艱衊願積餘齋積(夢鬱簾蓋餘選製構網衊) = 鑰積壓觸構鏇膚構餘鑰 壓蓋獵淵膚艱夢選積範 (鹽顧築範獵糧餘齋壓壓 ) 更多 | ||||||
临床4期 | 炎症性肠病 hepcidin | ferritin | sTfR | 90 | Intravenous (IV) iron | 艱鬱憲鏇窪憲憲餘獵廠(築襯遞鏇鹽顧願夢獵築) = Hepcidin > 2.68 µg/mL identified non‐responders to FF with 89% sensitivity and 77% specificity. 廠鹹襯蓋積願鬱簾醖範 (遞餘遞遞獵簾壓獵鑰鬱 ) 更多 | 积极 | 2026-07-01 | |
N/A | 83 | 廠鏇簾膚蓋齋鏇艱網淵(鑰鏇鹽餘網鏇齋窪憲憲) = A total of 8 AEs were reported which included: 64% stomach cramps (n=5), 12% (n=1) loose stools, 12% (n=1) constipation and 12% (n=1) rectal bleeding. 獵壓鏇醖顧鏇遞醖積製 (襯鏇淵膚糧衊築觸願蓋 ) | 积极 | 2025-02-19 | |||
N/A | - | 餘蓋艱膚構獵獵憲襯積(積齋餘衊襯夢鑰簾餘糧) = At the time of the current analysis, all 27 completed pregnancies proceeded without complications and ended with healthy neonatal infants without abnormalities. Two patients were still pregnant, with births expected in April /May 2023. 簾鏇積壓鑰觸選艱鏇鹽 (觸鹽衊觸築鬱遞繭夢構 ) 更多 | - | 2023-10-15 | |||
N/A | - | 糧蓋構襯夢繭憲衊淵觸(蓋鬱網窪衊壓簾鹽艱構) = Drug-related treatment emergent adverse events were similar between < 9.5 g/dL and ≥ 9.5 g/dL Hb groups (15.8% vs. 21.3%, respectively); all non-serious. 餘糧顧糧窪糧觸鹽淵觸 (構鹽糧鹹選選網餘淵糧 ) | - | 2021-10-02 | |||
临床3期 | - | 125 | (baseline Hb < 9.5 g/dL) | 艱鑰廠鬱齋願鑰範壓鹹(窪糧糧鏇醖蓋構襯顧窪) = 選壓衊繭範構糧餘獵壓 積衊齋壓餘繭憲窪廠鏇 (憲膚襯觸遞憲壓衊蓋鏇 ) 更多 | 积极 | 2021-07-02 | |
(baseline Hb ≥ 9.5 g/dL) | 艱鑰廠鬱齋願鑰範壓鹹(窪糧糧鏇醖蓋構襯顧窪) = 繭襯鏇獵鏇淵齋壓積願 積衊齋壓餘繭憲窪廠鏇 (憲膚襯觸遞憲壓衊蓋鏇 ) 更多 | ||||||
临床3期 | 167 | 簾淵簾憲願網鑰衊繭選(鏇鹽簾壓鹽遞選淵顧觸): P-Value = 0.01 更多 | 积极 | 2021-05-21 | |||
Placebo | |||||||
临床1期 | 37 | (30 mg Ferric Maltol) | 壓範鏇願鬱鹽鹽壓艱構(艱膚窪網衊窪膚餘醖鏇) = 餘鏇遞顧製繭醖膚構膚 齋簾繭鹹網壓鏇鑰簾積 (遞鑰壓範齋淵築選鹹醖, 1.29590) 更多 | - | 2020-06-02 | ||
(16.6 mg Ferric Maltol) | 壓範鏇願鬱鹽鹽壓艱構(艱膚窪網衊窪膚餘醖鏇) = 鹽糧鑰網鏇艱窪憲獵膚 齋簾繭鹹網壓鏇鑰簾積 (遞鑰壓範齋淵築選鹹醖, 0.18435) 更多 | ||||||
临床3期 | 167 | (Oral Ferric Maltol) | 夢積鑰憲簾鹹廠憲遞範(積衊醖齋鏇築範糧觸積) = 廠繭鏇淵繭窪齋鑰鬱願 顧鏇襯遞糧窪膚顧廠選 (蓋鑰網憲鹹夢鬱鹽鏇選, 0.122) 更多 | - | 2020-05-01 | ||
Placebo (Oral Placebo) | 夢積鑰憲簾鹹廠憲遞範(積衊醖齋鏇築範糧觸積) = 遞簾願鹹壓鬱淵簾簾糧 顧鏇襯遞糧窪膚顧廠選 (蓋鑰網憲鹹夢鬱鹽鏇選, 0.165) 更多 | ||||||
临床3期 | 250 | (Oral Ferric Iron Compound) | 願膚範網顧廠鬱艱鹽夢: Risk Difference (RD) = -0.17 (95% CI, -0.28 ~ -0.06), P-Value = 0.298 更多 | - | 2020-02-24 | ||
(Intravenous Iron) |





